Evidence mapPaperPMID 41208334Full record

ReviewJournal of cosmetic dermatology2025

Hyalase in Dermatology: Applications Beyond Filler Management.

Saba Hasanzadeh, Parisa Farokh, Golsa Sadat Hosseini, Maryam Abbasian, Ifa Etesami, Shirin Zaresharifi, Sahar Dadkhahfar

Abstract readReview
In one paragraph

Review in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saba HasanzadehSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0005-0121-0610
Parisa FarokhSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Golsa Sadat HosseiniSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam AbbasianDepartment of Science, Rutgers, the State University of New Jersey, New Brunswick, New Jersey, USA.
Ifa EtesamiAutoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-3026-2485
Shirin ZaresharifiSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4002-6953
Sahar DadkhahfarSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4058-2562

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyaluronic acid (HA) is a key extracellular matrix component in the skin. Hyaluronidase is an enzyme that breaks down HA into monosaccharides. The FDA has approved this enzyme for hypodermoclysis, drug absorption enhancement, and subcutaneous urography. The most common application of this enzyme is the dissolution of HA fillers.

aimThis study aimed to explore the various applications of hyaluronidase beyond its common medical uses. Moreover, we illustrate the mechanism by which this enzyme is helpful in conditions such as drug extravasation, scleroderma, scleromyxedema, and keloids.

methodsA comprehensive review of hyaluronidase applications in medicine, with a specific focus on dermatology, was conducted using PubMed/MEDLINE, the Cochrane Library, and Embase. The conditions under which hyaluronidase was applied are discussed, and the protocols used for each condition are evaluated and summarized.

resultsHyaluronidase improves tissue permeability and enhances drug delivery. Therefore, it is beneficial for treating keloids, managing pain, and enhancing the distribution of chemotherapeutic agents within tumors. It is also useful for reducing fibrosis in scleroderma, scleromyxedema, and chronic GVHD. Hyaluronidase is considered a safe drug, and its adverse effects are infrequent.

conclusionHyaluronidase has the potential to be useful for various medical and dermatological conditions. Further research is required to fill existing gaps and establish standardized usage protocols.

Indexed as

Dermal FillersHyaluronic AcidHyaluronoglucosaminidaseSkin DiseasesDermatologyHumansKeloidScleromyxedemaSkinDermal FillersHyaluronic AcidHyaluronoglucosaminidasedermatologyextravasationfibrosisGVHDhyaluronidasekeloidmicrostomia

Identifiers

PMID41208334
PMCPMC12598384

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.